InNexus Announces Achieving Business Milestone in Development of Intracellular SuperAntibody(TM) Therapeutics

17-Mar-2005

InNexus Biotechnology Inc. announced the achievement of a business milestone in the development of intracellular SuperAntibody(TM) therapeutics. With the receipt of the first of three high affinity anti-apoptosis monoclonal antibodies from its co-development partner, Epitomics, Inc., InNexus has established an important foundation on which to advance SuperAntibody(TM) platform based drugs from early-stage testing to eventual commercialization.

Commenting on the announcement, Dr. A. Charles Morgan, President of InNexus, said: "The antibody transfer marks an early and critical milestone in the development of intracellular SuperAntibody(TM) therapeutics. Utilizing our TransMAb(TM) technology platform, the newly enhanced TransMab antibodies will be able to enter inside cells to either turn on or turn off the apoptotic process, leading to the creation of new, useful and never before seen medications in areas as stroke and cancer."

Garth Likes, Vice President of Business Development added: "Using our TransMAb(TM) technology platform, we are able to regulate cellular functions and believe it represents a new paradigm in the use of antibodies and SuperAntibodies(TM) for the development of novel therapeutics and diagnostics."

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures